Neoparin (Enoxaparin Sodium)

Enoxaparin Sodium, the active ingredient in Neoparin, is a low molecular weight heparin presented as a sterile injectable solution for subcutaneous, intravenous, or haemodialysis use. It is employed to prevent and treat thromboembolic disorders in adult patients at risk of clot formation.

GNH USA supplies Neoparin as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide, providing regulatory‑approved batches to healthcare institutions across multiple regions.

Neoparin, a low molecular weight heparin, is used in clinical settings to manage and prevent thrombotic conditions.

- Prevention of venous thromboembolism: reduces the risk of clot formation in patients undergoing surgery or prolonged immobilisation. - Treatment of deep vein thrombosis: facilitates clot resolution and prevents propagation in diagnosed DVT cases. - Prevention of clotting during haemodialysis: maintains circuit patency by inhibiting coagulation during dialysis sessions.

Adverse reactions to Neoparin may vary in frequency and severity.

Common Side Effects: - Injection site bruising or pain. - Mild bleeding such as epistaxis or gum bleeding. - Nausea or abdominal discomfort. - Headache. - Transient elevation of liver enzymes.

Serious or Rare Side Effects: - Major hemorrhage (intracranial, gastrointestinal, or surgical site). - Heparin‑induced thrombocytopenia (HIT). - Spinal or epidural hematoma. - Severe allergic reactions (anaphylaxis, urticaria). - Adrenal cortical hemorrhage.

Before initiating Neoparin, clinicians should evaluate patient‑specific risk factors and monitor for complications. - Renal impairment: adjust dose or monitor anti‑Xa activity. - History of bleeding: assess risk and consider alternative therapy. - Concurrent anticoagulants: avoid additive bleeding risk. - Pregnancy: use only when benefit outweighs potential fetal risk. - Surgery or invasive procedures: discontinue according to protocol before the procedure. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Neoparin may interact with other medicines that affect haemostasis or renal clearance.

Major Interactions (Avoid): - Warfarin: increased risk of severe bleeding. - Dual antiplatelet therapy (aspirin plus clopidogrel): additive haemorrhagic effect. - Thrombolytic agents (e.g., alteplase): potentiates anticoagulation.

Moderate Interactions (Monitor Closely): - NSAIDs: may increase gastrointestinal bleeding. - Renally cleared drugs (e.g., aminoglycosides): monitor anti‑Xa activity. - Hormone replacement therapy: may elevate clot risk.